Even though the August profit release may cause some price weakness, Morgans prefers to get in early with a upgrade to Add, given the share price is -10% below the broker’s target price of $6.92. The post-result weakness may arise from limited hospital access in the last few months.
Read MoreShare price of Nanosonics has been relatively stable during this period of pandemic-generated volatility, observes Morgans.
Read More
Sam Twidale, Portfolio Manager for the DNR Capital Australian Emerging Companies Fund, explains why he believes recent volatility in equity markets has provided some excellent opportunities in the smaller cap sector.
Read More
Andrew Page of Strawman.com highlights three Australian companies with net cash and zero debt that should offer safe harbour at this time.
Read More
DNR Capital Portfolio Manager Sam Twidale last discussed Nanosonics (ASX:NAN) back in April 2019. Since that time the share price has rallied strongly from the mid $4 level back in April to touching $7 since reporting in late August.The DNR Capital Australian Emerging Companies Fund currently holds a 6% position in Nanosonics.
Read MoreThe share price has rallied over 30% in the last month and Morgans downgrades to Hold from Add. Second half operating earnings (EBITDA) are forecast to be less than the first half so, potentially, some weakness is likely to follow when the company reports in late August.
Read More
trophon’s high-frequency ultrasonic vibrations generate a sonically activated, supercharged hydrogen peroxide (H2O2) mist that kills bacteria, fungi and viruses.
Read More
Tap into trophon2 the latest innovation in automated ultrasound probe high-level disinfection. Easy to Set up, Simple to Use that delivers fast and efficient workflows… so you have more time to focus on your patients.
Read More
DNR Capital’s Sam Twidale shares some insights with Informed Investor about Sydney-based medical technology company Nanosonics (ASX: NAN).
Read MoreThe broker has remodeled its assumptions for Nanosonics with regard management equipment service agreements and also added in contributions form new products.
Read MoreDecember quarter sales were up 41% on the prior quarter, as North American direct sales gained momentum. Morgans adjusts its revenue growth assumptions to 40% from 25% to reflect the stronger installed base in the US.
Read More
Medical device maker Nanosonics (NAN) may be a small Australian company, but it has high-powered support in rolling out its innovative disinfection technology.
Read More
Small-cap broker interest in Nanosonics is relatively broad, but Baillieu has jumped ahead of the pack with a TP of $1.15, a 30-35% lift on current trade.
Read More